

VioQuest Pharmaceuticals, Inc.
 Form 4
 June 17, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 LENZ BRIAN

2. Issuer Name and Ticker or Trading Symbol
 VioQuest Pharmaceuticals, Inc.
 [VQPH]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 180 MT. AIRY ROAD, SUITE 102
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 06/13/2008

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 CFO and Treasurer

BASKING RIDGE, NJ 07920

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock					1,500 ⁽¹⁾	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title
Warrant	\$ 4 ⁽¹⁾							06/29/2007	06/29/2012	Common Stock, \$.001 par value
Warrant	\$ 1 ⁽¹⁾							04/09/2008	04/09/2013	Common Stock
Series B Convertible Preferred Stock	\$ 3.8 ⁽¹⁾							03/14/2008	⁽⁸⁾	Series A Convertible Preferred Stock
Series A Convertible Preferred Stock	\$ 0.6 ⁽¹⁾							04/09/2008	⁽⁸⁾	Common Stock
Stock Options	\$ 16.7 ⁽¹⁾	06/13/2008		D ⁽²⁾			1,500 ⁽¹⁾	⁽²⁾	10/06/2013	Common Stock
Stock Options	\$ 0.54	06/13/2008		A ⁽²⁾		1,500		⁽²⁾	10/06/2013	Common Stock
Stock Options	\$ 14 ⁽¹⁾	06/13/2008		D ⁽³⁾			2,500 ⁽¹⁾	⁽³⁾	04/19/2014	Common Stock
Stock Options	\$ 0.54	06/13/2008		A ⁽³⁾		2,500		⁽³⁾	04/19/2014	Common Stock
Stock Options	\$ 10.8 ⁽¹⁾	06/13/2008		D ⁽⁴⁾			6,000 ⁽¹⁾	⁽⁴⁾	01/24/2015	Common Stock
Stock Options	\$ 0.54	06/13/2008		A ⁽⁴⁾		6,000		⁽⁴⁾	01/24/2015	Common Stock
Stock Options	\$ 10.3 ⁽¹⁾	06/13/2008		D ⁽⁵⁾			10,000 ⁽¹⁾	⁽⁵⁾	11/29/2015	Common Stock
Stock Options	\$ 0.54	06/13/2008		A ⁽⁵⁾		10,000		⁽⁵⁾	11/29/2015	Common Stock
Stock Options	\$ 8.5 ⁽¹⁾	06/13/2008		D ⁽⁶⁾			10,000 ⁽¹⁾	⁽⁶⁾	03/31/2016	Common Stock
Stock Options	\$ 0.54	06/13/2008		A ⁽⁶⁾		10,000		⁽⁶⁾	03/31/2016	Common Stock
Stock Options	\$ 5.5 ⁽¹⁾	06/13/2008		D ⁽⁷⁾			10,000 ⁽¹⁾	⁽⁷⁾	05/11/2007	Common Stock

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.